Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.52 |
| ▸ | SYK | P43405 | 1/20 | 0.49 |
| ▸ | PGR | P06401 | 3/20 | 0.47 |
| ▸ | AR | P10275 | 1/20 | 0.47 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.46 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.46 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.46 |
| ▸ | GABRA3 | P34903 | 3/20 | 0.46 |
| ▸ | XDH | P47989 | 1/20 | 0.46 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.46 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 2/20 | 0.45 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | GRM5 | P41594 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7386770 | 0.90 | CLK4 (0.53) | CLK4PGRARGABRG2GABRB3 | |
| SCHEMBL7506044 | 0.88 | CLK4 (0.45) | CLK4SYKPGRARGABRG2 | |
| SCHEMBL22570759 | 0.88 | CLK4 (0.45) | CLK4SYKPGRARGABRG2 | |
| SCHEMBL21480441 | 0.86 | GRM5 (0.50) | CLK4SYKPGRARXDH | |
| SCHEMBL28579957 | 0.85 | ALDH1A1 (0.50) | CLK4ARGRM5 | |
| SCHEMBL2154026 | 0.85 | CLK4 (0.65) | CLK4PGRGABRG2GABRB3GABRA5 | |
| SCHEMBL4443914 | 0.84 | ALDH1A1 (0.52) | CLK4PGRARGABRG2GABRB3 | |
| SCHEMBL17051411 | 0.84 | AR (0.50) | CLK4ARGRM5 | |
| SCHEMBL16201506 | 0.84 | AR (0.50) | CLK4ARGRM5 | |
| SCHEMBL24099540 | 0.83 | GRM5 (0.45) | CLK4SYKPGRARGABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220336752-A1 | Organic Electroluminescent Element, Material for Organic Electroluminescent Element, Light Emitting Device, Display Device and Lighting Device Each Using Said Element, and Compound Used for Said Element | UDC IRELAND LIMITED (IE) | 2022-10-20 | — | — | US | disclosed |
| US-11171293-B2 | Organic electroluminescent element, material for organic electroluminescent element, light emitting device, display device and lighting device each using said element, and compound used for said element | UDC IRELAND LIMITED (IE) | 2021-11-09 | — | — | US | disclosed |
| US-20140319507-A1 | Organic Electroluminescent Element, Material for Organic Electroluminescent Element, Light Emitting Device, Display Device and Lighting Device Each Using Said Element, and Compound Used for Said Element | UDC IRELAND LIMITED (IE) | 2014-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220336752-A1 | Organic Electroluminescent Element, Material for Organic Electroluminescent Element, Light Emitting Device, Display Device and Lighting Device Each Using Said Element, and Compound Used for Said Element | L1CAM, NR2E3, OR10J3 | CLK4 827/4885SYK 3211/4885PGR 1499/4885 |
| US-11171293-B2 | Organic electroluminescent element, material for organic electroluminescent element, light emitting device, display device and lighting device each using said element, and compound used for said element | L1CAM, OR10J3, INTS9 | CLK4 1033/4885SYK 2997/4885PGR 1920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.